Navigation Links
Acorda Therapeutics to Host Analyst and Investor Reception

ual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders. The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. For full prescribing information, please go to www.zanaflexcapsules.com. Acorda's lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Contact

Acorda Therapeutics
Erica Wishner, 914-347-4300 ext. 162
ewishner@acorda.com


'"/>




Page: 1 2

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Acorda Therapeutics Host Analyst and Investor Reception
(Date:8/27/2014)... , August 27, 2014 ... Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental Lasers), Current ... by MarketsandMarkets, the global Dental Equipment Market is expected ... million in 2014, growing at a CAGR of ... 95 market data tables and 61 figures spread ...
(Date:8/27/2014)... Aug. 27, 2014 Pulse Systems, Inc. , ... Practice Management , and Revenue Cycle Management (RCM) ... practices performed by some RCM vendors, at UBM Medica,s ... on September 19-20, 2014.  A presenter ... in September with a new session encouraging practices to "Look ...
(Date:8/27/2014)... 2014 Sihuan Pharmaceutical Holdings Group Ltd. ... leading pharmaceutical company with the largest cardio-cerebral vascular ... prescription drug market, today announced the unaudited ... (collectively the "Group") for the six months ended ... HighlightsFor the Six months ended 30 JuneKey Income ...
Breaking Medicine Technology:Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 2Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 4Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
... 2012 Quest International, Inc., a leading global supplier ... announced today that is has contributed $5000 to the ... American Cancer Society Key Gala, that benefits the Boston ... on Thursday, March 29, 2012. "We are ...
... Access NOW! (PCPAN) coalition today applauded the United Mine Workers ... Express Scripts, Inc. (ESI) and Medco Health Solutions, two ... the Federal Trade Commission (FTC), the UMW said the ... union mine workers. UMW is a growing ...
Cached Medicine Technology:Quest International Donates $5000 to the American Cancer Society 2Nationwide Coalition Applauds United Mine Workers For Voicing Concern Over Proposed ESI/Medco Merger 2
(Date:8/27/2014)... WEDNESDAY, Aug. 27, 2014 (HealthDay News) -- A new ... an effective treatment for seniors with sleep apnea. ... obstructive sleep apnea, a condition in which the airway ... interrupted sleep that leads to daytime drowsiness. ... stream of air through a patient,s nose via a ...
(Date:8/27/2014)... from our parents shapes many aspects of our lives. ... epigenome that is set during development, but can be ... by those of our parents and grandparents. , The ... supporting proteins that determine whether genes are expressed or ... our own health, but also that it may be ...
(Date:8/27/2014)... Boston, MA (PRWEB) August 27, 2014 Tejal ... Patient Safety Foundation (NPSF) and the NPSF Lucian Leape ... announced in the August 25 issue of Modern Healthcare magazine. ... MD, PhD; and Andrew Sussman, MD, MBA; NPSF Lucian ... Gary Kaplan, MD, who is a member of both the ...
(Date:8/27/2014)... August 27, 2014 Scientists at The Scripps ... a specific signaling pathway can be associated with alcohol ... a gene, called neurofibromatosis type 1 (Nf1), which TSRI ... The new research shows Nf1 regulates gamma-aminobutyric acid (GABA), ... relaxation. , "This novel and seminal study provides ...
(Date:8/27/2014)... Georgia State University’s Center for Leadership in Disability ... the Maternal and Child Health Bureau of the ... of the Autism Plan for Georgia, aimed at ... spectrum disorder. , In preparing for this project, ... of key stakeholders from across Georgia. The resulting ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea Treatment Helps Seniors, Study Finds 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 4Health News:NPSF President Among 100 Most Influential in Health Care 2Health News:NPSF President Among 100 Most Influential in Health Care 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2
... Adlyfe, a private company,developing novel diagnostic testing ... that it has appointed Roxanne Duan, Ph.D.,as Vice ... for overseeing,the Adlyfe,s Research efforts and will report ... to Adlyfe with nearly two decades of experience. ...
... 17 Symmetry Medical Inc.,(NYSE: SMA ), ... orthopedic,device industry and other medical markets, announced today ... http://www.symmetrymedical.com, which contains improved,user- friendly features. ... languages, provides easy to,find product information and a ...
... concludes, , , MONDAY, Sept. 17 (HealthDay News) -- ... asthma you develop, new research suggests. , The ... countries had more allergy-triggered asthma symptoms than did ... "The link between atopic sensitization and asthma symptoms ...
... YORK -- Before a new treatment becomes available, researchers ... in clinical research trials. But finding these patients is ... studies or unable to participate due do logistical hurdles. ... novel treatment approaches -- and beneficial new therapies take ...
... SAN DIEGO, Sept. 17 CryoCor, Inc. (Nasdaq:,CRYO), a ... announced today that Edward F. Brennan, President and Chief,Executive ... to present at the Maxim Group First Annual Growth ... at 10:00 a.m. ET at The Grand,Hyatt Hotel. ...
... address the nation,s largest public health challenges, including AIDS, should be ... ... plans, WASHINGTON, Sept. 17 ... next President to,commit to ending the AIDS epidemic in America. They ...
Cached Medicine News:Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 2Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 3Health News:Symmetry Medical Launches New Global Web site 2Health News:Symmetry Medical Launches New Global Web site 3Health News:Allergy-Induced Asthma More Common in Affluent Countries 2Health News:Allergy-Induced Asthma More Common in Affluent Countries 3Health News:IMPACT initiative looks to improve patient participation in clinical trials 2Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 3
... designed to give reliable performance for all mixing ... button, power supply socket and fuse holder are ... The speed knob is located on the bottom ... a minimum 950 rpm to a maximum of ...
ThermoPrep 3's two systems in "one" approach, its capability to accommodate up to two standard microplates and its user-selectable settings offers the versatility and throughput you need in today's l...
... only four-color, automated benchtop flow cytometry system ... sorting. Designed specifically to support a wide ... software instrument control, auto-sample loading, and push-button ... FACSCalibur is fully modular so it can ...
... cytometer especially suited for cell analysis ... CyFlow allows to analyze scatter signals ... fluorescence channels. Data acquisition, analysis, and ... built-in PC employing Partec DPAC software, ...
Medicine Products: